Nothing Special   »   [go: up one dir, main page]

MX2021000516A - Composicion farmaceutica para usarse en el tratamiento o prevencion de una enfermedad relacionada con c5 y metodo para tratar o prevenir una enfermedad relacionada con c5. - Google Patents

Composicion farmaceutica para usarse en el tratamiento o prevencion de una enfermedad relacionada con c5 y metodo para tratar o prevenir una enfermedad relacionada con c5.

Info

Publication number
MX2021000516A
MX2021000516A MX2021000516A MX2021000516A MX2021000516A MX 2021000516 A MX2021000516 A MX 2021000516A MX 2021000516 A MX2021000516 A MX 2021000516A MX 2021000516 A MX2021000516 A MX 2021000516A MX 2021000516 A MX2021000516 A MX 2021000516A
Authority
MX
Mexico
Prior art keywords
related disease
prevention
treating
preventing
treatment
Prior art date
Application number
MX2021000516A
Other languages
English (en)
Inventor
Kenji Shinomiya
Keisuke Gotanda
Jun-Ichi Nishimura
Erica Winter
Joy C Hsu
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of MX2021000516A publication Critical patent/MX2021000516A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a composiciones farmacéuticas para usarse en el tratamiento o prevención de una enfermedad relacionada con C5 y métodos para tratar o prevenir una enfermedad relacionada con C5. La presente invención además se refiere a dosificaciones y administraciones de anticuerpo anti-C5 o composiciones farmacéuticas que contienen el anticuerpo.
MX2021000516A 2018-08-01 2019-08-01 Composicion farmaceutica para usarse en el tratamiento o prevencion de una enfermedad relacionada con c5 y metodo para tratar o prevenir una enfermedad relacionada con c5. MX2021000516A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862713211P 2018-08-01 2018-08-01
US201862764952P 2018-08-17 2018-08-17
US201862760204P 2018-11-13 2018-11-13
PCT/JP2019/030283 WO2020027279A1 (en) 2018-08-01 2019-08-01 A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease

Publications (1)

Publication Number Publication Date
MX2021000516A true MX2021000516A (es) 2021-04-12

Family

ID=67660420

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021000516A MX2021000516A (es) 2018-08-01 2019-08-01 Composicion farmaceutica para usarse en el tratamiento o prevencion de una enfermedad relacionada con c5 y metodo para tratar o prevenir una enfermedad relacionada con c5.

Country Status (21)

Country Link
US (1) US20210301004A1 (es)
EP (2) EP3829628B1 (es)
JP (3) JP6672516B2 (es)
KR (5) KR20210038697A (es)
CN (1) CN112512563A (es)
AU (2) AU2019315213B2 (es)
BR (1) BR112021001655A2 (es)
CA (1) CA3107618A1 (es)
CR (1) CR20210103A (es)
DE (1) DE112019003835T5 (es)
ES (1) ES2980137T3 (es)
HR (1) HRP20240823T1 (es)
HU (1) HUE067057T2 (es)
IL (1) IL280475A (es)
MX (1) MX2021000516A (es)
PH (1) PH12021550226A1 (es)
PL (1) PL3829628T3 (es)
RS (1) RS65630B1 (es)
SG (1) SG10202002898RA (es)
TW (2) TWI704157B (es)
WO (1) WO2020027279A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101479381B (zh) 2006-03-31 2015-04-29 中外制药株式会社 调控抗体血液动力学的方法
AU2008304778B9 (en) 2007-09-26 2014-05-08 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in CDR
PT2275443E (pt) 2008-04-11 2016-03-15 Chugai Pharmaceutical Co Ltd Moléculas de ligação ao antigénio capazes de se ligarem, repetidamente, a duas ou mais moléculas de antigénio
CN103328632A (zh) 2010-11-30 2013-09-25 中外制药株式会社 与多分子的抗原重复结合的抗原结合分子
PL3233921T3 (pl) 2014-12-19 2022-01-10 Chugai Seiyaku Kabushiki Kaisha Przeciwciała anty-c5 i sposoby ich stosowania
AU2017305073B2 (en) 2016-08-05 2024-02-01 Chugai Seiyaku Kabushiki Kaisha Composition for prevention or treatment of IL-8 related diseases

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
EP0714409A1 (en) 1993-06-16 1996-06-05 Celltech Therapeutics Limited Antibodies
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
ES2292236T3 (es) 1998-04-02 2008-03-01 Genentech, Inc. Variantes de anticuerpos y sus fragmentos.
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
PL220113B1 (pl) 1999-01-15 2015-08-31 Genentech Inc Wariant macierzystego polipeptydu zawierającego region Fc, polipeptyd zawierający wariant regionu Fc o zmienionym powinowactwie wiązania receptora Fc gamma (FcγR), polipeptyd zawierający wariant regionu Fc o zmienionym powinowactwie wiązania noworodkowego receptora Fc (FcRn), kompozycja, wyizolowany kwas nukleinowy, wektor, komórka gospodarza, sposób otrzymywania wariantu polipeptydu, zastosowanie wariantu polipeptydu i sposób otrzymywania wariantu regionu Fc
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP2113516B1 (en) 2000-10-10 2014-05-21 Genentech, Inc. Antibodies against C5 inhibiting type II endothelial cell activation
JP4958387B2 (ja) 2001-08-17 2012-06-20 ジェネンテック， インコーポレイテッド Ｃ５ｂの形成を妨害することなくｃ５及びｃ５ａに結合する補体経路阻害剤
ITMI20021527A1 (it) 2002-07-11 2004-01-12 Consiglio Nazionale Ricerche Anticorpi anti componente c5 del complemento e loro uso
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
DK1572744T3 (da) 2002-12-16 2010-09-20 Genentech Inc Immunoglobulinvarianter og deres anvendelser
US20070116710A1 (en) 2004-02-03 2007-05-24 Leonard Bell Methods of treating hemolytic anemia
US20050169921A1 (en) 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease
SI1737891T1 (sl) 2004-04-13 2013-05-31 F.Hoffmann-La Roche Ag Protitelesa proti selektinu p
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
CA2645810C (en) 2006-03-15 2018-12-11 Alexion Pharmaceuticals, Inc. Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
PT2275443E (pt) 2008-04-11 2016-03-15 Chugai Pharmaceutical Co Ltd Moléculas de ligação ao antigénio capazes de se ligarem, repetidamente, a duas ou mais moléculas de antigénio
AU2009279197B2 (en) 2008-08-05 2013-12-12 Novartis Ag Compositions and methods for antibodies targeting complement protein C5
HRP20230167T1 (hr) 2008-11-10 2023-03-31 Alexion Pharmaceuticals, Inc. Postupci i pripravci za liječenje poremećaja povezanih s komplementom
PE20130393A1 (es) 2010-03-11 2013-04-07 Rinat Neuroscience Corp Anticuerpos con union de antigenos dependiente de ph
TWI667346B (zh) 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的FcRn親和力之抗體
AU2014213147B2 (en) * 2013-01-31 2019-01-17 lmmunAbs Inc. C5 antibody and method for preventing and treating complement-related diseases
PL3233921T3 (pl) * 2014-12-19 2022-01-10 Chugai Seiyaku Kabushiki Kaisha Przeciwciała anty-c5 i sposoby ich stosowania
KR101892883B1 (ko) * 2015-02-27 2018-10-05 추가이 세이야쿠 가부시키가이샤 Il-6 관련 질환 치료용 조성물
WO2017123636A1 (en) * 2016-01-11 2017-07-20 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment
EP3408291A1 (en) 2016-01-25 2018-12-05 Shire Human Genetic Therapies, Inc. Anti-c5 antibodies with enhanced ph switch
JP7518764B2 (ja) * 2017-10-26 2024-07-18 アレクシオン ファーマシューティカルズ， インコーポレイテッド 発作性夜間ヘモグロビン尿症（ＰＮＨ）および非典型溶血性尿毒症症候群（ａＨＵＳ）の処置のための抗Ｃ５抗体の投薬量および投与
KR20200095485A (ko) * 2017-12-04 2020-08-10 라 파마슈티컬스 인코포레이티드 보체 활성의 조절인자

Also Published As

Publication number Publication date
JP2020073608A (ja) 2020-05-14
US20210301004A1 (en) 2021-09-30
EP4445913A2 (en) 2024-10-16
CN112512563A (zh) 2021-03-16
ES2980137T3 (es) 2024-09-30
RS65630B1 (sr) 2024-07-31
BR112021001655A2 (pt) 2021-05-04
AU2024205486A1 (en) 2024-08-22
KR20210038697A (ko) 2021-04-07
TW202024128A (zh) 2020-07-01
PH12021550226A1 (en) 2021-10-11
CA3107618A1 (en) 2020-02-06
EP3829628C0 (en) 2024-05-15
JP2020019769A (ja) 2020-02-06
IL280475A (en) 2021-03-01
CR20210103A (es) 2021-03-22
AU2019315213A1 (en) 2021-03-25
JP2020079331A (ja) 2020-05-28
TWI701041B (zh) 2020-08-11
KR20200033225A (ko) 2020-03-27
DE112019003835T5 (de) 2021-05-27
KR20200033348A (ko) 2020-03-27
JP6672533B1 (ja) 2020-03-25
KR20210037743A (ko) 2021-04-06
HUE067057T2 (hu) 2024-09-28
EP3829628A1 (en) 2021-06-09
TW202019467A (zh) 2020-06-01
AU2019315213B2 (en) 2024-05-02
WO2020027279A1 (en) 2020-02-06
SG10202002898RA (en) 2020-05-28
KR20240115904A (ko) 2024-07-26
EP3829628B1 (en) 2024-05-15
PL3829628T3 (pl) 2024-08-19
JP6672516B2 (ja) 2020-03-25
HRP20240823T1 (hr) 2024-09-27
TWI704157B (zh) 2020-09-11

Similar Documents

Publication Publication Date Title
PH12019501706A1 (en) A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
PH12021550226A1 (en) A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
PH12018500642A1 (en) Anti-garp antibody
MX2022004072A (es) Anticuerpos de factor xi y metodos de uso.
MX2020001774A (es) Composiciones y métodos para tratar enfermedad colestásica.
EA036102B9 (ru) Терапевтические средства с углевод-опосредованной адресной доставкой
EA201891853A1 (ru) Способы лечения или предотвращения атеросклероза путем введения ингибитора angptl3
MX2020013808A (es) Antagonista de gremlina-1 para la prevencion y el tratamiento del cancer.
PH12016501820A1 (en) Il-21 antibodies
EA201990988A1 (ru) Антитела против chikv и пути их применения
MX2018009662A (es) Metodo y composicion farmaceutica para tratamiento de neurodegeneracion.
MX2020001164A (es) Composicion para su uso en la prevencion y/o el tratamiento de la mucositis orogastrointestinal inducida por un tratamiento oncologico.
MX2020009496A (es) Metodo para tratar asma o enfermedad alergica.
MX2020013621A (es) Composiciones y metodos de tratamiento de vih.
EA202090827A1 (ru) Пероральные композиции для лечения гастроэзофагеального рефлюкса
MX2020007050A (es) Una combinacion de inmunoglobulina plasmatica e inmunoglobulina especifica de antigeno para la modificacion del sistema inmune y el tratamiento o prevencion de enfermedades alergicas.
MX2020011377A (es) Metodos y composiciones para el tratamiento de urticaria cronica.
MX2021001228A (es) Composicion para uso en la prevencion y/o tratamiento de la mucosa genitourinaria.
EA202090944A1 (ru) Анти-cd3-антитело и фармацевтическая композиция для лечения онкологических заболеваний, содержащая его
SG10201705954VA (en) A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
MX2021001393A (es) Composiciones para el tratamiento de la enfermedad de injerto contra huesped.
MX2022001411A (es) Metodos para tratar o prevenir canceres que implican la administracion de agentes receptores anti-ccr5.
MX2020013923A (es) Anticuerpos anti molécula de adhesión celular l1 (l1cam) y usos de estos.
WO2018030881A3 (ko) 맥락막 질환의 치료를 위한 갑상선 호르몬의 용도
SG10201700775YA (en) A Pharmaceutical Composition For Use In The Treatment Or Prevention Of A C5-Related Disease And A Method For Treating Or Preventing A C5-Related Disease